EndoChoice's platform of gastrointestinal products and services will be on display during Digestive Disease Week (DDW), May 17-20 in Washington, D.C.
Products from EndoChoice’s Imaging, Devices, Diagnostics, and Single-Use specialty areas will be available for hands-on demonstration at EndoChoice’s booth throughout the entire week.
The company will also be launching new innovations including Fuse Full Spectrum Endoscopy Generation 2, Boa Polypectomy Snare, Neptune Injection Needle, and a quality measures program that will simplify the task of tracking key GI procedure measures such as adenoma detection rates (ADR).
"The mission of EndoChoice is to serve the GI caregiver by providing innovative products. Each year, DDW provides us with an opportunity to allow physicians to experience EndoChoice products that we believe will enable them to provide even higher levels of care for their patients," said Mark Gilreath, founder and CEO at EndoChoice.
EndoChoice is a medtech company focused on the manufacturing and commercialization of platform technologies including endoscopic imaging systems, devices and infection control products and pathology services for specialists screening, diagnosing and treating a wide range of gastrointestinal conditions, including colon cancer.